Literature DB >> 27537549

Functional assessment of tyrosinase variants identified in individuals with albinism is essential for unequivocal determination of genotype-to-phenotype correlation.

M Mondal1, M Sengupta1, K Ray1.   

Abstract

BACKGROUND: Oculocutaneous albinism type 1 (OCA1), caused by pathogenic variations in the tyrosinase gene (TYR), is the most frequent and severe form of hypopigmentary disorder worldwide. While OCA1A manifests as a complete loss of melanin pigment, patients with OCA1B show residual pigmentation of the skin, hair and eyes. Limited experimental evidence suggests retention of TYR in the endoplasmic reticulum (ER) causes OCA1 pathogenesis. However, a comprehensive functional analysis of TYR missense variations and correlation with genotype is lacking.
OBJECTIVES: Functional characterization of nonsynonymous tyrosinase variants in patients with OCA1 reported in the Albinism Database, dbSNP and the published literature, and an attempt to correlate them with reported and predicted phenotypes.
METHODS: Thirty-four reported missense variants of TYR were subcloned by site-directed mutagenesis, and the dual-enzyme activities of the variant proteins were compared with the wild-type. The degree of ER retention was also checked for each of the variants through endoglycosidase H (Endo H) digestion followed by immunoprecipitation and densitometric analysis.
RESULTS: Functional studies revealed one reported OCA1A variation with nearly 100% enzyme activity, 10 OCA1B variants lacking any enzyme activity, eight nonsynonymous single-nucleotide polymorphisms (SNPs) with ~30-70% of enzyme activity, and three SNPs that completely lacked activity altogether. The Endo H assay corroborated these results.
CONCLUSIONS: Loss of enzyme activity of TYR variants was completely in agreement with ER retention across all variants examined. The results of the assay clearly established that determination of the biological activity of identified variants in patients with OCA is essential to correlate the identified suspect genotype with the obvious phenotype of the disease.
© 2016 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27537549     DOI: 10.1111/bjd.14977

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Identification of a functionally significant tri-allelic genotype in the Tyrosinase gene (TYR) causing hypomorphic oculocutaneous albinism (OCA1B).

Authors:  Chelsea S Norman; Luke O'Gorman; Jane Gibson; Reuben J Pengelly; Diana Baralle; J Arjuna Ratnayaka; Helen Griffiths; Matthew Rose-Zerilli; Megan Ranger; David Bunyan; Helena Lee; Rhiannon Page; Tutte Newall; Fatima Shawkat; Christopher Mattocks; Daniel Ward; Sarah Ennis; Jay E Self
Journal:  Sci Rep       Date:  2017-06-30       Impact factor: 4.379

2.  Evidence that the Ser192Tyr/Arg402Gln in cis Tyrosinase gene haplotype is a disease-causing allele in oculocutaneous albinism type 1B (OCA1B).

Authors:  Siying Lin; Aida Sanchez-Bretaño; Joseph S Leslie; Katie B Williams; Helena Lee; N Simon Thomas; Jonathan Callaway; James Deline; J Arjuna Ratnayaka; Diana Baralle; Melanie A Schmitt; Chelsea S Norman; Sheri Hammond; Gaurav V Harlalka; Sarah Ennis; Harold E Cross; Olivia Wenger; Andrew H Crosby; Emma L Baple; Jay E Self
Journal:  NPJ Genom Med       Date:  2022-01-13       Impact factor: 6.083

3.  Identification and characterization of two novel noncoding tyrosinase (TYR) gene variants leading to oculocutaneous albinism type 1.

Authors:  Chaoyi Li; Qian Chen; Junjiao Wu; Jie Ren; Mengfei Zhang; Huakun Wang; Jinchen Li; Yu Tang
Journal:  J Biol Chem       Date:  2022-04-10       Impact factor: 5.486

4.  Genetic Causes of Oculocutaneous Albinism in Pakistani Population.

Authors:  Zureesha Sajid; Sairah Yousaf; Yar M Waryah; Tauqeer A Mughal; Tasleem Kausar; Mohsin Shahzad; Ali R Rao; Ansar A Abbasi; Rehan S Shaikh; Ali M Waryah; Saima Riazuddin; Zubair M Ahmed
Journal:  Genes (Basel)       Date:  2021-03-28       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.